60 Degrees Pharmaceuticals Inc (SXTP)

$2.07 -0.09 (-4.17%)
Market Cap 3.05M
Revenue (ttm) 680,000.00
Net Income (ttm) -7.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,169.12%
Debt to Equity Ratio 0.00
Volume 659,200
Avg Vol 344,586
Day's Range N/A - N/A
Shares Out 1.47M
Stochastic %K 14%
Beta 2.88
Analysts Sell
Price Target $7.00

Company Profile

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidi...

Industry: Biotechnology
Sector: Healthcare
Phone: 202 327 5422
Address:
1025 Connecticut Avenue NW, Suite 1000, Washington, United States
Buying_another
Buying_another Jun. 20 at 2:58 PM
$SXTP wow what is this junk
0 · Reply
globaldaytraderzzzzzzz
globaldaytraderzzzzzzz Jun. 20 at 9:04 AM
$SXTP watch for big up swing
0 · Reply
Buying_another
Buying_another Jun. 16 at 3:15 PM
$SXTP insane what trash
0 · Reply
Neegud
Neegud Jun. 12 at 2:25 PM
$JAGX $SINT $SVRE $SXTP $WINT SVRE is 300k float now.
1 · Reply
LimitCess
LimitCess Jun. 12 at 2:20 PM
$SINT $WINT $SXTP $SVRE If you like low floats peep $JAGX known runner
0 · Reply
Delfan02
Delfan02 Jun. 11 at 4:09 PM
$RMSL can't wait to make a years worth of salary in one trade. When this thing hits anywhere near .05 you best believe it! $IXHL Just bought some, but I'm scared. Hopefully PR soon? $SXTP What the actual f*@&?
4 · Reply
Buying_another
Buying_another Jun. 11 at 2:06 PM
$SXTP gross
1 · Reply
Love_To_Learn
Love_To_Learn Jun. 10 at 2:42 PM
$SXTP communicating with the RFL folks due to SXTP being enmeshed with BEUD from b4 as well as CYTH downloading metadata to allow new tracks to be placed down for us to move forward $RFL
0 · Reply
Buying_another
Buying_another Jun. 10 at 2:33 PM
$SXTP fuck
0 · Reply
Buying_another
Buying_another Jun. 6 at 7:08 PM
$SXTP ok some inside buys that’s nice
0 · Reply
Latest News on SXTP
60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

Jun 4, 2025, 8:56 AM EDT - 19 days ago

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

Jun 3, 2025, 8:49 AM EDT - 20 days ago

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

May 15, 2025, 4:31 PM EDT - 5 weeks ago

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

Apr 22, 2025, 8:44 AM EDT - 2 months ago

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

Apr 10, 2025, 8:31 AM EDT - 2 months ago

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

Apr 8, 2025, 8:31 AM EDT - 2 months ago

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Feb 21, 2025, 9:00 AM EST - 4 months ago

60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

FTHM

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

Feb 20, 2025, 10:36 AM EST - 4 months ago

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

Feb 11, 2025, 12:59 PM EST - 4 months ago

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 6, 2025, 2:07 PM EST - 4 months ago

60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 5, 2025, 9:22 AM EST - 4 months ago

60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 30, 2025, 2:20 PM EST - 5 months ago

60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

Jan 28, 2025, 8:01 AM EST - 5 months ago

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

Jan 8, 2025, 8:02 AM EST - 5 months ago

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

Dec 23, 2024, 8:57 AM EST - 6 months ago

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital

Dec 11, 2024, 8:56 AM EST - 6 months ago

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital

VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Dec 2, 2024, 4:05 PM EST - 7 months ago

VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

VSEE

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nov 22, 2024, 9:00 AM EST - 7 months ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

CANF

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results

Nov 14, 2024, 2:31 PM EST - 7 months ago

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

Oct 3, 2024, 9:02 AM EDT - 9 months ago

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

Hyliion Holdings And 2 Other Stocks Under $5 Executives Are Buying

Sep 12, 2024, 7:19 AM EDT - 10 months ago

Hyliion Holdings And 2 Other Stocks Under $5 Executives Are Buying

HYLN COCH

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Sep 4, 2024, 8:00 AM EDT - 10 months ago

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

Aug 28, 2024, 2:48 PM EDT - 10 months ago

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results

Aug 14, 2024, 11:01 AM EDT - 11 months ago

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

Aug 12, 2024, 9:12 AM EDT - 11 months ago

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split

Aug 6, 2024, 9:26 AM EDT - 11 months ago

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split

60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support

Jul 25, 2024, 9:02 AM EDT - 11 months ago

60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

Jul 19, 2024, 8:29 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

Jul 9, 2024, 6:31 AM EDT - 1 year ago

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind

Jun 27, 2024, 7:59 AM EDT - 1 year ago

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind

Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind

May 30, 2024, 7:59 AM EDT - 1 year ago

Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind

60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study

May 20, 2024, 7:59 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study

60 Degrees Pharmaceuticals Announces First Quarter 2024 Results

May 15, 2024, 1:45 PM EDT - 1 year ago

60 Degrees Pharmaceuticals Announces First Quarter 2024 Results

60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases

May 8, 2024, 7:59 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required

May 2, 2024, 7:59 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required

60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis

Apr 3, 2024, 7:58 AM EDT - 1 year ago

60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis

60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024

Mar 14, 2024, 7:59 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024

60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris

Feb 20, 2024, 7:59 AM EST - 1 year ago

60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris

60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer

Feb 8, 2024, 7:59 AM EST - 1 year ago

60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer

WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

Jan 31, 2024, 12:00 PM EST - 1 year ago

WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering

Jan 31, 2024, 11:15 AM EST - 1 year ago

60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering

WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

Jan 30, 2024, 9:45 AM EST - 1 year ago

WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering

Jan 30, 2024, 9:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering

60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting

Jan 22, 2024, 7:59 AM EST - 1 year ago

60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting

60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements

Jan 16, 2024, 7:59 AM EST - 1 year ago

60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements

60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024

Dec 26, 2023, 7:59 AM EST - 1 year ago

60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024

60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease

Nov 15, 2023, 7:29 AM EST - 1 year ago

60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease

60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston

Oct 19, 2023, 8:31 AM EDT - 1 year ago

60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston

60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases

Oct 12, 2023, 4:16 PM EDT - 1 year ago

60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases

60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements

Sep 18, 2023, 4:16 PM EDT - 1 year ago

60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements

Buying_another
Buying_another Jun. 20 at 2:58 PM
$SXTP wow what is this junk
0 · Reply
globaldaytraderzzzzzzz
globaldaytraderzzzzzzz Jun. 20 at 9:04 AM
$SXTP watch for big up swing
0 · Reply
Buying_another
Buying_another Jun. 16 at 3:15 PM
$SXTP insane what trash
0 · Reply
Neegud
Neegud Jun. 12 at 2:25 PM
$JAGX $SINT $SVRE $SXTP $WINT SVRE is 300k float now.
1 · Reply
LimitCess
LimitCess Jun. 12 at 2:20 PM
$SINT $WINT $SXTP $SVRE If you like low floats peep $JAGX known runner
0 · Reply
Delfan02
Delfan02 Jun. 11 at 4:09 PM
$RMSL can't wait to make a years worth of salary in one trade. When this thing hits anywhere near .05 you best believe it! $IXHL Just bought some, but I'm scared. Hopefully PR soon? $SXTP What the actual f*@&?
4 · Reply
Buying_another
Buying_another Jun. 11 at 2:06 PM
$SXTP gross
1 · Reply
Love_To_Learn
Love_To_Learn Jun. 10 at 2:42 PM
$SXTP communicating with the RFL folks due to SXTP being enmeshed with BEUD from b4 as well as CYTH downloading metadata to allow new tracks to be placed down for us to move forward $RFL
0 · Reply
Buying_another
Buying_another Jun. 10 at 2:33 PM
$SXTP fuck
0 · Reply
Buying_another
Buying_another Jun. 6 at 7:08 PM
$SXTP ok some inside buys that’s nice
0 · Reply
FilingTracker
FilingTracker Jun. 6 at 12:59 AM
$SXTP Insider increases position by 46.2% via 5,000 share purchase at $2.88/share: https://www.sec.gov/Archives/edgar/data/1946563/000121390025051700/xslF345X05/ownership.xml
0 · Reply
Buying_another
Buying_another Jun. 5 at 6:22 PM
$SXTP trash
0 · Reply
_www_larval_com_
_www_larval_com_ Jun. 5 at 4:42 PM
$SXTP has stumbled -12% lower to -2% (~210Kv) a few minutes ago, follow for more volatility.
0 · Reply
BobAxe
BobAxe Jun. 5 at 1:28 PM
$SXTP 3 break, lets see 3.50s then 4 push!
0 · Reply
BobAxe
BobAxe Jun. 5 at 1:27 PM
$SXTP 😎
0 · Reply
Buying_another
Buying_another Jun. 5 at 12:23 PM
$SXTP come on let’s get to 4$ today
0 · Reply
AlphaView_
AlphaView_ Jun. 4 at 8:18 PM
$ALZN primed runner for premarket $CMG $SXTP $MBRX $WKEY ww
0 · Reply
digitalspurs1
digitalspurs1 Jun. 4 at 7:05 PM
$SXTP drug is available in all major pharmacies (including Amazon Pharmacy!) and they have growing revenues. 4 million market cap is very undervalued. Price precedes volume! This will be found soon!
0 · Reply
Gazzy7
Gazzy7 Jun. 4 at 6:17 PM
$SXTP Can someone poke this with a stick
0 · Reply
jsimmons1992
jsimmons1992 Jun. 4 at 3:40 PM
$SXTP Someone is playing a very expensive game of chicken right now with this stock 😳
1 · Reply
oneplayaday
oneplayaday Jun. 4 at 3:30 PM
$SXTP this could explode any minute
0 · Reply
ProTraderColin
ProTraderColin Jun. 4 at 3:11 PM
$SXTP wow now dumping. These names are pure gambles
0 · Reply